Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.71 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | AGXT | P21549 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9071087 | 1.00 | TAAR1 (0.71) | TAAR1ADRB2IDO1AGXTCHRM2 | |
| SCHEMBL11333474 | 1.00 | TAAR1 (0.71) | TAAR1ADRB2IDO1AGXTCHRM2 | |
| SCHEMBL29365903 | 1.00 | TAAR1 (0.71) | TAAR1ADRB2IDO1AGXTCHRM2 | |
| SCHEMBL6224557 | 0.87 | TAAR1 (0.73) | TAAR1ADRB2IDO1AGXTCHRM2 | |
| SCHEMBL449889 | 0.85 | TAAR1 (0.76) | TAAR1ADRB2IDO1AGXTCHRM2 | |
| SCHEMBL9935171 | 0.84 | TAAR1 (0.50) | TAAR1ADRB2 | |
| SCHEMBL27302315 | 0.84 | TAAR1 (0.64) | TAAR1ADRB2IDO1AGXTCHRM2 | |
| SCHEMBL1416802 | 0.84 | TAAR1 (0.50) | TAAR1ADRB2 | |
| SCHEMBL6204552 | 0.84 | TAAR1 (0.64) | TAAR1ADRB2IDO1AGXTCHRM2 | |
| (S)-M-Methoxyamphetamine SCHEMBL3293027 | 0.83 | TAAR1 (1.00) | TAAR1IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106631717-B | A kind of preparation method of 3- (2- aminopropyl) phenol | 上海再启生物技术有限公司 | 2019-11-22 | — | — | CN | claimed |
| CN-106631717-A | Method for preparing 3-(2-aminopropyl)phenol | 上海再启生物技术有限公司 | 2017-05-10 | — | — | CN | claimed |
| EP-3931183-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | VENTHERA, INC. | 2024-03-21 | — | — | US | disclosed |
| CN-116332910-A | 2-aminopyrimidine derivatives as kinase inhibitors, preparation and use thereof | 江苏威凯尔医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-114008024-A | Compounds having iron death inducing activity and methods of using the same | 费罗治疗公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
| CN-106631717-B | A kind of preparation method of 3- (2- aminopropyl) phenol | 上海再启生物技术有限公司 | 2019-11-22 | — | — | CN | disclosed |
| CN-105814055-B | As the condensed imidazole and pyrazole derivatives of TNF active regulators | UCB生物制药私人有限公司 | 2017-05-31 | — | — | CN | disclosed |
| EP-1773750-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006013399-A1 | PHARMACEUTICAL INTERMEDIATES AND A PROCESS FOR THE PREPARATION THEREOF | EGIS Gyógyszergyár Rt. (HU) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006002185-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| US-6887867-B2 | 5H-2,3-benzodiazepine antagonists of excitatory amino acid receptors | TRANSGENOMIC, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1296960-A2 | 5H-2,3-BENZODIAZEPINE ANTAGONISTS OF EXCITATORY AMINO ACID RECEPTORS | Annovis, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020025958-A1 | 5H-2,3-benzodiazepine antagonists of excitatory amino acid receptors | TRANSGENOMIC, INC. | 2002-02-28 | — | — | US | disclosed |
| WO-2001098280-A2 | 5H-2,3-BENZODIAZEPINE ANTAGONISTS OF EXCITATORY AMINO ACID RECEPTORS | ANNOVIS, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-0007516-B1 | 7-ALPHA-METHYL-ESTROGENS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN FURTHER PROCESSING | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-10-28 | — | — | EP | disclosed |
| EP-0007516-A2 | 7-Alpha-methyl-estrogens, process for their preparation and their use in further processing | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | TAAR1 4158/4885ADRB2 4687/4885IDO1 3185/4885 |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | TAAR1 4158/4885ADRB2 4687/4885IDO1 3185/4885 |
| US-11040964-B2 | Compounds and methods of use | AIFM2, GPX4, GPX1 | TAAR1 4158/4885ADRB2 4687/4885IDO1 3185/4885 |
| US-20020025958-A1 | 5H-2,3-benzodiazepine antagonists of excitatory amino acid receptors | GRIN2A, GRIN3A, GABRE | TAAR1 359/4885ADRB2 327/4885IDO1 2599/4885 |
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, SLC40A1, GPX4 | TAAR1 3024/4885ADRB2 3879/4885IDO1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.